Mario Turri-Zanoni, Gianluca Dalfino, Matt Lechner, Iacopo Dallan, Paolo Battaglia, Carla Facco, Francesca Franzi, Giacomo Gravante, Marco Ferrari, Dimitrios Terzakis, Amrita Jay, Martin D Forster, Andrea Luigi Ambrosoli, Maurizio Bignami, Christos Georgalas, Philippe Herman, Piero Nicolai, Valerie J Lund, Paolo Castelnuovo
{"title":"双表型鼻窦肉瘤:欧洲多中心病例系列和系统文献综述。","authors":"Mario Turri-Zanoni, Gianluca Dalfino, Matt Lechner, Iacopo Dallan, Paolo Battaglia, Carla Facco, Francesca Franzi, Giacomo Gravante, Marco Ferrari, Dimitrios Terzakis, Amrita Jay, Martin D Forster, Andrea Luigi Ambrosoli, Maurizio Bignami, Christos Georgalas, Philippe Herman, Piero Nicolai, Valerie J Lund, Paolo Castelnuovo","doi":"10.14639/0392-100X-N2087","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Biphenotypic sinonasal sarcoma (BSNS) is a rare low-grade cancer that was included from the 4th edition of WHO classification of head and neck tumours. The purpose of this study is to analyse clinical behaviour, pattern of recurrences and survival outcomes of this neoplasm.</p><p><strong>Methods: </strong>Retrospective review of patients affected by BSNS who were treated via an endoscopic-assisted approach in 6 European tertiary-care referral hospitals. Cases of BSNS described in literature since 2012 to date were fully reviewed, according to PRISMA guidelines.</p><p><strong>Results: </strong>A total of 15 patients were included. Seven patients were treated via an endoscopic endonasal approach, 4 with endoscopic transnasal craniectomy, and 4 via a cranio-endoscopic approach. Adjuvant treatment was delivered in 2 cases. After a mean follow-up of 27.3 months, systemic metastasis was observed in 1 case; the 5-year overall survival and disease-free survival rates were 100% and 80 ± 17.9%, respectively.</p><p><strong>Conclusions: </strong>BSNS is a locally aggressive tumour with a low recurrence rate and encouraging survival outcomes if properly treated with surgical resection and free margins followed by adjuvant radiotherapy for selected cases. Endoscopic-assisted surgery is safe and effective as an upfront treatment within a multidisciplinary care protocol.</p>","PeriodicalId":6890,"journal":{"name":"Acta Otorhinolaryngologica Italica","volume":"42 6","pages":"545-553"},"PeriodicalIF":2.1000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/a7/aoi-2022-06-545.PMC9853106.pdf","citationCount":"1","resultStr":"{\"title\":\"Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review.\",\"authors\":\"Mario Turri-Zanoni, Gianluca Dalfino, Matt Lechner, Iacopo Dallan, Paolo Battaglia, Carla Facco, Francesca Franzi, Giacomo Gravante, Marco Ferrari, Dimitrios Terzakis, Amrita Jay, Martin D Forster, Andrea Luigi Ambrosoli, Maurizio Bignami, Christos Georgalas, Philippe Herman, Piero Nicolai, Valerie J Lund, Paolo Castelnuovo\",\"doi\":\"10.14639/0392-100X-N2087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Biphenotypic sinonasal sarcoma (BSNS) is a rare low-grade cancer that was included from the 4th edition of WHO classification of head and neck tumours. The purpose of this study is to analyse clinical behaviour, pattern of recurrences and survival outcomes of this neoplasm.</p><p><strong>Methods: </strong>Retrospective review of patients affected by BSNS who were treated via an endoscopic-assisted approach in 6 European tertiary-care referral hospitals. Cases of BSNS described in literature since 2012 to date were fully reviewed, according to PRISMA guidelines.</p><p><strong>Results: </strong>A total of 15 patients were included. Seven patients were treated via an endoscopic endonasal approach, 4 with endoscopic transnasal craniectomy, and 4 via a cranio-endoscopic approach. Adjuvant treatment was delivered in 2 cases. After a mean follow-up of 27.3 months, systemic metastasis was observed in 1 case; the 5-year overall survival and disease-free survival rates were 100% and 80 ± 17.9%, respectively.</p><p><strong>Conclusions: </strong>BSNS is a locally aggressive tumour with a low recurrence rate and encouraging survival outcomes if properly treated with surgical resection and free margins followed by adjuvant radiotherapy for selected cases. Endoscopic-assisted surgery is safe and effective as an upfront treatment within a multidisciplinary care protocol.</p>\",\"PeriodicalId\":6890,\"journal\":{\"name\":\"Acta Otorhinolaryngologica Italica\",\"volume\":\"42 6\",\"pages\":\"545-553\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/a7/aoi-2022-06-545.PMC9853106.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Otorhinolaryngologica Italica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14639/0392-100X-N2087\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Otorhinolaryngologica Italica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14639/0392-100X-N2087","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review.
Objective: Biphenotypic sinonasal sarcoma (BSNS) is a rare low-grade cancer that was included from the 4th edition of WHO classification of head and neck tumours. The purpose of this study is to analyse clinical behaviour, pattern of recurrences and survival outcomes of this neoplasm.
Methods: Retrospective review of patients affected by BSNS who were treated via an endoscopic-assisted approach in 6 European tertiary-care referral hospitals. Cases of BSNS described in literature since 2012 to date were fully reviewed, according to PRISMA guidelines.
Results: A total of 15 patients were included. Seven patients were treated via an endoscopic endonasal approach, 4 with endoscopic transnasal craniectomy, and 4 via a cranio-endoscopic approach. Adjuvant treatment was delivered in 2 cases. After a mean follow-up of 27.3 months, systemic metastasis was observed in 1 case; the 5-year overall survival and disease-free survival rates were 100% and 80 ± 17.9%, respectively.
Conclusions: BSNS is a locally aggressive tumour with a low recurrence rate and encouraging survival outcomes if properly treated with surgical resection and free margins followed by adjuvant radiotherapy for selected cases. Endoscopic-assisted surgery is safe and effective as an upfront treatment within a multidisciplinary care protocol.
期刊介绍:
Acta Otorhinolaryngologica Italica first appeared as “Annali di Laringologia Otologia e Faringologia” and was founded in 1901 by Giulio Masini.
It is the official publication of the Italian Hospital Otology Association (A.O.O.I.) and, since 1976, also of the Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale (S.I.O.Ch.C.-F.).
The journal publishes original articles (clinical trials, cohort studies, case-control studies, cross-sectional surveys, and diagnostic test assessments) of interest in the field of otorhinolaryngology as well as clinical techniques and technology (a short report of unique or original methods for surgical techniques, medical management or new devices or technology), editorials (including editorial guests – special contribution) and letters to the Editor-in-Chief.
Articles concerning science investigations and well prepared systematic reviews (including meta-analyses) on themes related to basic science, clinical otorhinolaryngology and head and neck surgery have high priority.